Return to work following meningioma surgery: a Swedish nationwide registry-based matched cohort study.

meningioma neurosurgery quality of life

Journal

Neuro-oncology practice
ISSN: 2054-2577
Titre abrégé: Neurooncol Pract
Pays: England
ID NLM: 101640528

Informations de publication

Date de publication:
Jun 2020
Historique:
entrez: 13 6 2020
pubmed: 13 6 2020
medline: 13 6 2020
Statut: ppublish

Résumé

Meningioma is the most common primary intracranial tumor. It is usually slow growing and benign, and surgery is the main treatment modality. There are limited data on return to work following meningioma surgery. The objective of this study was to determine the patterns of sick-leave rate prior to surgery, and up to 2 years after, in patients compared to matched controls. Data on patients ages 18 to 60 years with histologically verified intracranial meningioma between 2009 and 2015 were identified in the Swedish Brain Tumor Registry (SBTR) and linked to 3 national registries after 5 matched controls were assigned to each patient. We analyzed 956 patients and 4765 controls. One year prior to surgery, 79% of meningioma patients and 86% of controls were working ( There is a considerable risk for long term sick leave 2 years after meningioma surgery. Neurological impairment following surgery was a modifiable risk factor increasing the risk for long-term sick leave. More effective treatment of depression may facilitate return to work in this patient group.

Sections du résumé

BACKGROUND BACKGROUND
Meningioma is the most common primary intracranial tumor. It is usually slow growing and benign, and surgery is the main treatment modality. There are limited data on return to work following meningioma surgery. The objective of this study was to determine the patterns of sick-leave rate prior to surgery, and up to 2 years after, in patients compared to matched controls.
METHODS METHODS
Data on patients ages 18 to 60 years with histologically verified intracranial meningioma between 2009 and 2015 were identified in the Swedish Brain Tumor Registry (SBTR) and linked to 3 national registries after 5 matched controls were assigned to each patient.
RESULTS RESULTS
We analyzed 956 patients and 4765 controls. One year prior to surgery, 79% of meningioma patients and 86% of controls were working (
CONCLUSION CONCLUSIONS
There is a considerable risk for long term sick leave 2 years after meningioma surgery. Neurological impairment following surgery was a modifiable risk factor increasing the risk for long-term sick leave. More effective treatment of depression may facilitate return to work in this patient group.

Identifiants

pubmed: 32528713
doi: 10.1093/nop/npz066
pii: npz066
pmc: PMC7274187
doi:

Types de publication

Journal Article

Langues

eng

Pagination

320-328

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

Références

Stroke. 2002 Jan;33(1):179-85
pubmed: 11779908
World Neurosurg. 2018 Apr;112:64-72
pubmed: 29360583
Acta Oncol. 2015 Mar;54(3):377-84
pubmed: 25383446
J Neurosurg. 2015 Jan;122(1):4-23
pubmed: 25343186
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
J Neurooncol. 2012 Oct;110(1):137-44
pubmed: 22837023
Neurosurg Focus. 2015 Mar;38(3):E3
pubmed: 25727225
Neurosurgery. 2009 Jan;64(1):40-7; discussion 47
pubmed: 19145155
Int J Surg. 2014 Dec;12(12):1495-9
pubmed: 25046131
World Neurosurg. 2015 May;83(5):673-8
pubmed: 25655686
Lancet Oncol. 2016 Sep;17(9):e383-91
pubmed: 27599143
Circulation. 2016 Oct 4;134(14):999-1009
pubmed: 27507406
Scand J Public Health. 2010 Jul;38(5):541-7
pubmed: 20484307
PLoS One. 2017 Jan 6;12(1):e0169759
pubmed: 28061507
Int J Biol Markers. 2012 Dec 27;27(4):e322-30
pubmed: 23250772
Acta Neurochir (Wien). 2019 Feb;161(2):333-341
pubmed: 30675656
Brain Inj. 2018;32(13-14):1731-1739
pubmed: 30296173
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86
pubmed: 30445539
J Neurosurg. 2011 Aug;115(2):259-67
pubmed: 21529132
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Neuro Oncol. 2012 May;14(5):658-66
pubmed: 22406926
J Rehabil Med. 2018 Nov 7;50(10):879-885
pubmed: 30264851
Stroke. 1994 Apr;25(4):808-13
pubmed: 8160225
J Neurosurg. 2014 Apr;120(4):827-32
pubmed: 24484230
Neurosurgery. 2002 May;50(5):941-8; discussion 948-9
pubmed: 11950396
Med Care. 1998 Jan;36(1):8-27
pubmed: 9431328
J Neurosurg. 2017 Jan;126(1):201-211
pubmed: 27058201

Auteurs

Erik Thurin (E)

Institute of Neuroscience and Physiology, University of Gothenburg, Sahlgrenska Academy, Sweden.

Alba Corell (A)

Institute of Neuroscience and Physiology, University of Gothenburg, Sahlgrenska Academy, Sweden.
Department of Neurosurgery, Sahlgrenska University Hospital, Gothenburg, Sweden.

Sasha Gulati (S)

Department of Neurosurgery, St. Olav's University Hospital, Trondheim, Norway.
Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim.

Anja Smits (A)

Institute of Neuroscience and Physiology, University of Gothenburg, Sahlgrenska Academy, Sweden.
Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Department of Neuroscience, Neurology, Uppsala University, Sweden.

Roger Henriksson (R)

Department of Radiation Science and Oncology, University Hospital, Umeå, Sweden.

J Bartek (J)

Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden.
Department of Neuroscience and Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Department of Neurosurgery, Rigshospitalet, Copenhagen, Denmark.

Øyvind Salvesen (Ø)

Department of Public Health and General Practice, Norwegian University of Science and Technology, Trondheim.

Asgeir Store Jakola (AS)

Institute of Neuroscience and Physiology, University of Gothenburg, Sahlgrenska Academy, Sweden.
Department of Neurosurgery, Sahlgrenska University Hospital, Gothenburg, Sweden.
Department of Neurosurgery, St. Olav's University Hospital, Trondheim, Norway.

Classifications MeSH